Shares of Septerna Inc. (SEPN) are up over 65% at $11 in premarket trading Wednesday, after the company announced an exclusive global partnership with Novo Nordisk (NVO). The deal focuses on developing oral small-molecule drugs to treat obesity, type 2 diabetes, and other heart-related metabolic conditions.
Septerna specializes in creating drugs that target G protein-coupled receptors (GPCRs), using its unique Native Complex Platform. As part of the agreement, the two companies will start with four drug development programs aimed at specific GPCR targets, including GLP-1, GIP, and glucagon receptors.
For comments and feedback contact: editorial@rttnews.com
May 01, 2026 15:54 ET Central banks dominated the economics news flow this week with almost all major ones announcing their latest policy decisions and many boosted expectations for a rate hike in June. In other news, several countries released the preliminary data for first quarter economic growth. In the U.S., comments by Fed Chair Jerome Powell were also in focus as his term ends this month.